Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

FDA Approves New-Age NON-OPIOID Pain Relief Formula That Does NOT Shut Down Your Vital Organs Via Heroin Addiction. NEWS ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Utility stocks are often considered a safe haven during economic troubles, and Dominion Energy (NYSE: D) stands out as a prime candidate. With a substantial customer base of 3.6 million in Virginia, ...